Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer-An Opportunity for Targeted Therapy

被引：24

作者：

Harbin, Laura M. ^{[1
]}

Gallion, Holly H. ^{[1
]}

Allison, Derek B. ^{[2
]}

Kolesar, Jill M. ^{[1
,3
]}

机构：

[1] Univ Kentucky, Markey Canc Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Lexington, KY 40536 USA

[2] Univ Kentucky, Coll Med, Dept Pathol & Lab Med, Lexington, KY 40536 USA

[3] Univ Kentucky, Coll Pharm, Dept Pharm Practice & Sci, 760 Press Ave, Lexington, KY 40536 USA

来源：

DIAGNOSTICS | 2022年 / 12卷 / 04期

关键词：

next generation sequencing; precision medicine; ovarian cancer; targeted therapy; PARP inhibitors; immunotherapy; NTRK inhibitors; HOMOLOGOUS RECOMBINATION DEFICIENCY; MISMATCH-REPAIR DEFICIENCY; ANTITUMOR-ACTIVITY; ESMO RECOMMENDATIONS; MAINTENANCE THERAPY; CLINICAL ASSAYS; DOUBLE-BLIND; SAFETY; LAROTRECTINIB; INHIBITORS;

D O I：

10.3390/diagnostics12040842

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Ovarian cancer is the deadliest of all gynecologic malignancies claiming the lives of nearly 14,000 women in the United States annually. Despite therapeutic advances, the ovarian cancer mortality rate has remained stagnant since the 1980's. The molecular heterogeneity of ovarian cancers suggest they may be more effectively treated via precision medicine. Current guidelines recommend germline and somatic testing for all new epithelial ovarian cancer diagnoses to assist providers in identifying candidates for targeted therapies. Next generation sequencing (NGS) identifies targetable, driver, and novel mutations used to guide treatment decisions. Performing NGS is standard of care in many other malignancies, but for ovarian cancer the use of NGS in daily practice is still emerging. This review discusses the targetable genetic mutations and role of NGS and molecular biomarker testing in the treatment of ovarian cancer.

引用

页数：17

共 68 条

[1] PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome [J].

Alsaab, Hashem O. ;

Sau, Samaresh ;

Alzhrani, Rami ;

Tatiparti, Katyayani ;

Bhise, Ketki ;

Kashaw, Sushil K. ;

Iyer, Arun K. .

FRONTIERS IN PHARMACOLOGY, 2017, 8

[2] Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study. [J].

Andre, Thierry ;

Berton, Dominique ;

Curigliano, Giuseppe ;

Ellard, Susan ;

Trigo Perez, Jose Manuel ;

Arkenau, Hendrik-Tobias ;

Abdeddaim, Cyril ;

Moreno, Victor ;

Guo, Wei ;

Im, Ellie ;

Starling, Naureen .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)

[3] Ovarian Endometrioid Adenocarcinoma: Incidence and Clinical Significance of the Morphologic and Immunohistochemical Markers of Mismatch Repair Protein Defects and Tumor Microsatellite Instability [J].

Aysal, Anil ;

Karnezis, Anthony ;

Medhi, Irum ;

Grenert, James P. ;

Zaloudek, Charles J. ;

Rabban, Joseph T. .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2012, 36 (02) :163-172

[4] Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+T-lymphocytes predicts disease-free survival [J].

Bansal, Akriti ;

Srinivasan, Radhika ;

Rohilla, Manish ;

Rai, Bhavana ;

Rajwanshi, Arvind ;

Suri, Vanita ;

Chandra Saha, Subhas .

APMIS, 2021, 129 (05) :254-264

[5]

Barakat R.R., 2017, PRINCIPLES PRACTICE

[6] Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability-high tumors: A combined analysis of two cohorts in the GARNET study. [J].

Berton, Dominique ;

Banerjee, Susana N. ;

Curigliano, Giuseppe ;

Cresta, Sara ;

Arkenau, Hendrik-Tobias ;

Abdeddaim, Cyril ;

Kristeleit, Rebecca Sophie ;

Redondo, Andres ;

Leath, Charles A. ;

Torres, Antonio Anton ;

Guo, Wei ;

Im, Ellie ;

Andre, Thierry .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[7] Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer [J].

Bi, Fangfang ;

Chen, Ying ;

Yang, Qing .

CANCER CELL INTERNATIONAL, 2020, 20 (01)

[8] Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase [J].

Bryant, HE ;

Schultz, N ;

Thomas, HD ;

Parker, KM ;

Flower, D ;

Lopez, E ;

Kyle, S ;

Meuth, M ;

Curtin, NJ ;

Helleday, T .

NATURE, 2005, 434 (7035) :913-917

[9] Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden [J].

Chalmers, Zachary R. ;

Connelly, Caitlin F. ;

Fabrizio, David ;

Gay, Laurie ;

Ali, Siraj M. ;

Ennis, Riley ;

Schrock, Alexa ;

Campbell, Brittany ;

Shlien, Adam ;

Chmielecki, Juliann ;

Huang, Franklin ;

He, Yuting ;

Sun, James ;

Tabori, Uri ;

Kennedy, Mark ;

Lieber, Daniel S. ;

Roels, Steven ;

White, Jared ;

Otto, Geoffrey A. ;

Ross, Jeffrey S. ;

Garraway, Levi ;

Miller, Vincent A. ;

Stephens, Phillip J. ;

Frampton, Garrett M. .

GENOME MEDICINE, 2017, 9

[10] Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities [J].

Cheasley, Dane ;

Nigam, Abhimanyu ;

Zethoven, Magnus ;

Hunter, Sally ;

Etemadmoghadam, Dariush ;

Semple, Timothy ;

Allan, Prue ;

Carey, Mark S. ;

Fernandez, Marta L. ;

Dawson, Amy ;

Kobel, Martin ;

Huntsman, David G. ;

Le Page, Cecile ;

Mes-Masson, Anne-Marie ;

Provencher, Diane ;

Hacker, Neville ;

Gao, Yunkai ;

Bowtell, David ;

deFazio, Anna ;

Gorringe, Kylie L. ;

Campbell, Ian G. .

JOURNAL OF PATHOLOGY, 2021, 253 (01) :41-54

← 1 2 3 4 5 6 7 →